Review
Copyright ©The Author(s) 2015.
World J Clin Infect Dis. May 25, 2015; 5(2): 14-29
Published online May 25, 2015. doi: 10.5495/wjcid.v5.i2.14
Table 2 Treatment recommendations in Staphylococcus aureus with reduced vancomycin susceptibility infections1
General recommendations
Removal of indwelling hardware (prosthetic devices, surgical material, intravascular catheter, etc.)
Surgical debridement of infected wounds and abscess drainage Follow specific guidelines and local protocols, based on infection site, for treatment duration decisions
Antibiotic treatment considerations
VancomycinIf used aim: AUC0-24/MIC ≥ 400 or trough blood concentrations of 15-20 mg/L Careful monitoring of renal function is imperative
DaptomycinBactericidal. Good results with VISA and VRSA endovascular infections Consider administration of higher doses (i.e., 10 mg/kg per day) in severe infections and if vancomycin MIC > 2 μg/mL (including VISA)2 Consider synergic combinations (i.e., cloxacillin, aminoglycosides, betalactans, fosfomycin) in infections involving high inoculum (as in IE) and prosthetic devises It is inhibited by pulmonary surfactant, therefore should be avoided in SA respiratory or lung infections Monitor CK and liver function
LinezolidBacteriostatic Protein synthesis inhibitor. Inhibits bacterial toxin synthesis High tissue bioavailability Good results in SSTI and pneumonia (including VAP) Oral formulation with similar bioavailability Myelotoxicity: Monitor CBC Severe interactions with SSRIs and MAOIs, must not be given simultaneously
TigecyclineLow plasma concentrations. Bacteriostatic. Avoid monotherapy